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hence more time for follow-up and therapy adjustment, and
physicians who face drug reimbursement constraints.
THE UTILIZATION AND COSTS OF
PRESCRIPTION DRUGS IN A TEXAS MEDICAID
MANAGED CARE PILOT PROGRAM
Johnsrud MT, Lawson KA
University of Texas at Austin, Austin, TX, USA
The state of Texas established a Medicaid Managed Care
Pilot Program in Bexar County on September 1, 1996 for
clients previously in a Fee-For-Service (FFS) plan. Clients
selected either a health maintenance organization (HMO)
or a "gatekeeper" physician through a primary care case
management (PCCM) plan.
OBJECTIVE: This study evaluated the changes in prescrip-
tion utilization and costs when FFS clients entered into ei-
ther an HMO or PCCM health care delivery model.
METHODS: Prescription drug claims were analyzed for
Aid to Families with Dependent Children (AFDC) clients
eligible for both a pre-implementation period (December
1, 1995-May 31, 1996) and a post-implementation pe-
riod (December 1, 1996-May 31, 1997). A total of
59,377 HMO clients and 67,451 PCCM clients were
studied. Three control sites were selected consisting of
Medicaid clients in FFS, HMO, and PCCM plans for
both study periods in other geographical locations across
the state. Changes in the utilization and costs of prescrip-
tions per month were measured for each client between
the pre- and post-implementation periods.
RESULTS: One-way analysis of variance showed that the
mean change in monthly prescription costs per client was
highest between periods for clients in the PCCM experi-
mental group ($4.61, s.d. = $44.63), followed by HMO
clients in the experimental group ($2.10, s.d. = $26.21).
These cost increases were significantly higher than those
in the HMO ($0.68, s.d. = $34.91), PCCM ($1.44, s.d.
= $42.40), and FFS ($1.05, s.d. = 21.86) control groups
(p < 0.001). The percent of prescriptions dispensed as ge-
nerics increased across periods in all groups, except for
the PCCM experimental group.
CONCLUSION: Prescription drug costs may increase
when FFS Medicaid clients enter an HMO or PCCM
health care delivery plan.
POSTMARKETING OUTCOMES STUDIES:
BENEFITS AND RISKS
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OBJECTIVE: To consider the benefits, financial risks,
and opportunity costs of large postmarketing outcomes
studies as demonstrated by studies of the statin drugs.
METHODS: Literature review.
RESULTS: Benefits: The studies definitively showed that
45
the drugs and lowering lipids were safe and efficacious. The
studies also expanded the indications for the drugs, gener-
ated goodwill in the medical and research communities for
the sponsors, allowed them to include specific claims about
the drugs in their advertisements, generated follow-up stud-
ies, and spawned economic analyses that extended interest
in the drugs in both the medical and lay press and had a ma-
jor impact on the clinicians' use of the drug. Risks: The
studies had a strong coattails effect. Each new study was
beneficial to all the statins as well as the one studied. Eco-
nomic analyses after some of the studies concluded that
although the drugs effectively lowered cholesterol and pre-
vented clinical events, use of the drugs was not cost-
effective. Many studies took a long time, and it often took
even longer for the results to be assimilated, to be put into
perspective, and to influence other researchers and clini-
cians. During that time, the sponsoring companies shoul-
dered opportunity costs as well as the actual costs of the
studies. The risk that one drug company would use another
company's results instead of investing in their own research
did not materialize. All the major pharmaceutical companies
with statins conducted their own postmarketing outcomes
studies.
CONCLUSION: How a company weighs the risks and
benefits of strategic studies may depend on its time per-
spective. In the short term, the risks may outweigh the
benefits. Only those companies that have a longer per-
spective may find it beneficial to undertake a large post-
marketing study.
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The relationship between disease severity, quality of life
(QOL), and resource use in patients with atopic dermati-
tis (AD) has not been well explored in a managed care
population. As the overall lifetime incidence of AD is 15-
20%, this represents a substantial burden to the health-
care system.
OBJECTIVE: To investigate how severity of illness as-
sessed via chart review relates to patient-assessed severity,
QOL, and number of physician encounters.
METHODS: Questionnaires regarding AD severity (e.g.,
mild, moderate, severe) were mailed to 400 participants
identified from the claims database. Adults assessed their
QOL using the Dermatology Life Quality Index (DLQI)
and the Short Form 36 (SF-36), while children used the
Children's Dermatology Life Quality Index (CDLQI). The
number of physician visits for AD over the previous 12-
